NCT06779630View on ClinicalTrials.gov

Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions (BIOFLOW-48) Study

NARecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 18, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2031

Conditions
Coronary Artery Disease
Interventions
DEVICE

Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System

Orsiro Mission is composed of a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.

Trial Locations (7)

4031

RECRUITING

University hospital Basel, Basel

23795

RECRUITING

Segeberger Kliniken GmbH, Bad Segeberg

25304

RECRUITING

Charleston Area Medical Center, Charleston

67214

RECRUITING

Ascension Via Christi Hospitals Wichita, Wichita

78640

RECRUITING

Ascension Texas Cardiovascular, Kyle

90766

RECRUITING

Klinikum Fürth, Fürth

59-301

RECRUITING

Miedziowe Centrum Zdrowia SA, Lubin

Sponsors

Lead Sponsor

Biotronik, Inc.

Collaborators (1)

Biotronik AG
All Listed Sponsors
collaborator

Biotronik AG

INDUSTRY

lead

Biotronik, Inc.

INDUSTRY

NCT06779630 - Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions (BIOFLOW-48) Study | Biotech Hunter | Biotech Hunter